EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3 / CXCR7 antagonist, ACT ‐1004‐1239

Christine Huynh iD, Jasper Dingemanse iD, Henriette E Meyer Zu Schwabedissen iD, Marlene Fonseca iD, Patricia N Sidharta iD

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13883 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Christine Huynh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland. Hauptthemen laut MEDLINE: Itraconazole, Drug Interactions, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytochrome P450 (CYP) 3A4 is an enzyme involved in the metabolism of many drugs that are currently on the market and is therefore a key player in drug–drug interactions (DDIs). ACT‐1004‐1239 is a potent and selective, first‐in‐class ACKR3/CXRC7 antagonist being developed as a treatment for demyelinating diseases including multiple sclerosis. Based on the human absorption, distribution, metabolism, and excretion (ADME) study results, ACT‐1004‐1239 is predominantly metabolized by CYP3A4. This study investigated the effect of the strong CYP3A4 inhibitor, itraconazole, on the pharmacokinetics of single‐dose ACT‐1004‐1239 in healthy male subjects. In the open‐label, fixed‐sequence DDI study, a total of 16 subjects were treated. Each subject received a single dose of 10 mg ACT‐1004‐1239 (Treatment A) in the first period followed by concomitant administration of multiple doses of 200 mg itraconazole and a single dose of 10 mg ACT‐1004‐1239 in the second period. We report a median of difference in t max (90% confidence interval, CI) of 0.5 h (0.0, 1.0) comparing both treatments. The geometric mean ratio (GMR) (90% CI) of C max and AUC 0−∞ was 2.16 (1.89, 2.47) and 2.77 (2.55, 3.00), respectively. The GMR (90% CI) of t 1/2 was 1.46 (1.26, 1.70). Both treatments were well‐tolerated with an identical incidence in subjects reporting treatment‐emergent adverse events (TEAE). The most frequently reported TEAEs were headache and nausea. In conclusion, ACT‐1004‐1239 is classified as a moderately sensitive CYP3A4 substrate (i.e., increase of AUC ≥2‐ to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ItraconazoleDrug InteractionsCytochrome P-450 CYP3A InhibitorsCytochrome P-450 CYP3AHumansMaleAdultYoung AdultMiddle AgedHealthy VolunteersArea Under Curve

Substanzen

ItraconazoleCytochrome P-450 CYP3A InhibitorsCytochrome P-450 CYP3ACYP3A4 protein, human

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
  • Department of Pharmaceutical Sciences, Biopharmacy, University of Basel, Basel, Switzerland.
  • BlueClinical Phase 1, Hospital de Prelada, Porto, Portugal.

ORCID-Profile: Christine Huynh, Jasper Dingemanse, Henriette E Meyer Zu Schwabedissen, Marlene Fonseca, Patricia N Sidharta

Zitieren

APA

Huynh, C., Dingemanse, J., Meyer Zu Schwabedissen, H. E., Fonseca, M., & Sidharta, P. N. (2024). The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3 / CXCR7 antagonist, ACT ‐1004‐1239. Clinical and Translational Science. https://doi.org/10.1111/cts.13883

Vancouver

Huynh C, Dingemanse J, Meyer Zu Schwabedissen HE, Fonseca M, Sidharta PN. The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3 / CXCR7 antagonist, ACT ‐1004‐1239. Clinical and Translational Science. 2024. doi:10.1111/cts.13883

BibTeX
@article{Huynh2024,
  author = {Huynh, Christine and Dingemanse, Jasper and Meyer Zu Schwabedissen, Henriette E and Fonseca, Marlene and Sidharta, Patricia N},
  title = {The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3 / CXCR7 antagonist, ACT ‐1004‐1239},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13883}
}
Kostenlos starten →